Nov 26, 2024 · MariTide Demonstrated up to ~20% Average Weight Loss at 52 Weeks Without a Weight Loss Plateau in People Living With Obesity or Overweight. MariTide is the First Obesity Treatment With Monthly or Less Frequent Dosing to Demonstrate Safe and Effective Weight Loss in a Phase 2 Study

Nov 26, 2024 · •MariTide is the first obesity treatment with monthly or less frequent dosing to demonstrate safe and effective weight loss in a Phase 2 study •MariTide delivers substantial improvements across cardiometabolic parameters •MariTide benefits from Amgen’s longstanding track record of excellence in manufacturing

May 2, 2024 · MariTide, a GIPR antagonist conjugated to two GLP-1 analogues, now stands in the limelight. The obesity candidate, previously dubbed AMG 133, is currently being assessed in a phase 2...

Nov 27, 2024 · A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

Nov 28, 2024 · The U.S. biotech company Amgen announced this week that its investigational drug maridebart cafraglutide (MariTide) has demonstrated weight loss in patients with obesity, overweight, and/or Type 2 diabetes, in a double-blind, dose-ranging Phase 2 …

Nov 26, 2024 · Amgen announced today positive data from a 52-week phase 2 clinical trial of its investigational maridebart cafraglutide (MariTide) that showed substantial weight loss among people with obesity or overweight with or without type 2 diabetes (T2D) without plateaus.

Nov 26, 2024 · Amgen on Tuesday said its experimental weight loss injection helped patients with obesity lose up to 20% of their weight on average after a year in a critical mid-stage trial, as the company...

Amgen (AMGN) announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide – maridebart cafraglutide, formerly AMG 133 -, an investigational antibody peptide...

Sep 5, 2024 · Amgen is pushing its next-generation obesity therapy MariTide into a broad late-stage development program to assess the candidate’s potential in other weight-related conditions, such as heart, kidney and liver diseases.

Nov 26, 2024 · Amgen (AMGN) announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide – maridebart cafraglutide, formerly AMG 133 -, an investigational antibody peptide...